Rufinamide pretreatment attenuates ischemia-reperfusion injury in the gerbil hippocampus

Neurol Res. 2017 Nov;39(11):941-952. doi: 10.1080/01616412.2017.1362189. Epub 2017 Aug 7.

Abstract

Objectives: Rufinamide, a voltage-gated sodium channel (VGSC) blocker, is widely used for the clinical treatment of seizures associated with Lennox-Gastaut syndrome. Previous studies have demonstrated that VGSC blockers have neuroprotective properties against ischemic damage following experimental cerebral ischemia. However, protective effects of rufinamide against cerebral ischemic insults have not been addressed. Therefore, in the present study, we firstly examined neuroprotective effects of rufinamide using a gerbil model of transient global cerebral ischemia.

Methods: Gerbils were established by the occlusion of common carotid arteries for 5 min. The gerbils were divided into vehicle-treated sham-operated group, vehicle-treated ischemia-operated group, 50 and 100 mg/kg rufinamide-treated sham-operated groups, and 50 and 100 mg/kg rufinamide-treated ischemia-operated groups. Rufinamide was administrated intraperitoneally once daily for 3 days before ischemic surgery. To examine neuroprotective effects of rufinamide, we carried out cresyl violet staining, neuronal nuclear antigen immunohistochemistry and Fluoro-Jade B histofluorescence staining. In addition, we examined gliosis using immunohistochemistry for glial fibrillary acidic protein (a marker for astrocytes) and ionized calcium-binding adapter molecule 1 (a marker for microglia).

Results: We found that pre-treatment with 100 mg/kg of rufinamide effectively protected pyramidal neurons in the hippocampal cornus ammonis 1 (CA1) area after transient global cerebral ischemia. In addition, pre-treatment with 100 mg/kg of rufinamide significantly attenuated activations of astrocytes and microglia in the ischemic CA1 area.

Discussion: These findings suggest that rufinamide can display neuroprotective effect against cerebral ischemic insults and that its neuroprotective effect may involve the attenuation of ischemia-induced glial activation.

Keywords: Voltage-gated sodium channel; glial activation; hippocampal CA1 area; neuroprotective effect; pyramidal cells; transient global cerebral ischemia.

MeSH terms

  • Animals
  • Astrocytes / drug effects
  • Astrocytes / pathology
  • Astrocytes / physiology
  • Avoidance Learning / drug effects
  • Avoidance Learning / physiology
  • CA1 Region, Hippocampal / drug effects*
  • CA1 Region, Hippocampal / pathology
  • CA1 Region, Hippocampal / physiopathology
  • Carotid Artery Diseases / drug therapy
  • Carotid Artery Diseases / pathology
  • Carotid Artery Diseases / physiopathology
  • Disease Models, Animal
  • Gerbillinae
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / physiopathology
  • Male
  • Microglia / drug effects
  • Microglia / pathology
  • Microglia / physiology
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Neuroprotective Agents / administration & dosage*
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / pathology
  • Pyramidal Cells / physiology
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / pathology
  • Reperfusion Injury / physiopathology
  • Time Factors
  • Triazoles / administration & dosage*

Substances

  • Neuroprotective Agents
  • Triazoles
  • rufinamide